A Phase 3 pivotal confirmatory lead-in study of REM-001 in patients with cutaneous metastatic breast cancer (CMBC)

Status: Withdrawn prior to enrolment

Phase of Trial: Phase III

Latest Information Update: 29 Nov 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

13 Nov 2023 According to a Kintara Therapeutics media release, company is looking forward to enrolling the first patient in the 15 patient REM-001 study for cutaneous metastatic breast cancer.
09 Nov 2022 According to a Kintara Therapeutics media release, the company Paused the REM-001 program in Cutaneous Metastatic Breast Cancer (CMBC) to conserve cash which will be used to support the funding of the Company's ongoing international registrational study for VAL-083 in glioblastoma (GBM).
09 Nov 2022 Status changed from planning to withdrawn prior to enrolment, according to a Kintara Therapeutics media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com